circSETD3 Contributes to Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer by Targeting the miR-520h/ABCG2 Pathway

• Autori principali: Yutang Huang (Autore), Yi Dai (Autore), Chunjie Wen (Autore), Shuai He (Autore), Jingjing Shi (Autore), Dezhang Zhao (Autore), Lanxiang Wu (Autore), Honghao Zhou (Autore)
• Natura: Libro
• Pubblicazione: Elsevier, 2020-09-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Gefitinib is a first-line treatment for patients with non-small-cell lung cancer (NSCLC), but acquired resistance is a major obstacle to its therapeutic efficacy, and the underlying mechanisms are not fully elucidated. Recent studies have indicated that circular RNAs play a crucial role in chemoresi...